Charles Schwab Investment Management Inc Lexicon Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,417,295 shares of LXRX stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,417,295
Previous 1,359,148
4.28%
Holding current value
$1.18 Million
Previous $2.28 Million
2.54%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding LXRX
# of Institutions
141Shares Held
238MCall Options Held
459KPut Options Held
133K-
Artal Group S.A. Luxembourg, N4136MShares$113 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$32.3 Million3.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA11MShares$9.15 Million0.41% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$8.21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.09MShares$6.72 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $157M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...